Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherNon-Current ReceivablesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

ImmunityBio (IBRX) Non-Current Receivables (2016 - 2025)

ImmunityBio (IBRX) has disclosed Non-Current Receivables for 8 consecutive years, with $7.4 million as the latest value for Q4 2025.

  • Quarterly Non-Current Receivables rose 3.51% to $7.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.4 million through Dec 2025, up 3.51% year-over-year, with the annual reading at $7.4 million for FY2025, 3.51% up from the prior year.
  • Non-Current Receivables for Q4 2025 was $7.4 million at ImmunityBio, up from $7.3 million in the prior quarter.
  • The five-year high for Non-Current Receivables was $7.4 million in Q4 2025, with the low at $54000.0 in Q1 2021.
  • Average Non-Current Receivables over 5 years is $6.2 million, with a median of $6.8 million recorded in 2023.
  • The sharpest move saw Non-Current Receivables surged 11827.78% in 2022, then grew 3.33% in 2024.
  • Over 5 years, Non-Current Receivables stood at $6.4 million in 2021, then increased by 3.92% to $6.6 million in 2022, then grew by 4.09% to $6.9 million in 2023, then rose by 3.33% to $7.1 million in 2024, then increased by 3.51% to $7.4 million in 2025.
  • According to Business Quant data, Non-Current Receivables over the past three periods came in at $7.4 million, $7.3 million, and $7.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.